Dr Reddy's COO On US Derma Build-Up, One-Sided Biologics Norms
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories (DRL) appears to be building on plans for its differentiated dermatology and neurology formulations in the US after gains on the approvals front.
You may also be interested in...
Psoriasis Sprays: Niche Opportunities?
Expanding treatment options for psoriasis highlight how some firms are developing innovative "lower risk" assets that use established active ingredients but could provide benefits to specific patient segments.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
India IPR Wheels Are Turning: Novartis, Bayer, Sun, Legal Heads Discuss Realities
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.